Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Oct 17, 2023

Accession no.: 0001870913-23-000009
Filed: Oct 17, 2023
Trade date: Oct 13-16, 2023
Filing delay: 4 days
Rule 10b5-1 plan: Checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $1.45M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Shanmugam MuthusamyCIK 0001870913	Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Oct 13, 2023	Common Stock	SSaleDisposed	−11,937	$57.58^F2	−$687,332.46	1,070,683	Indirect
Oct 16, 2023	Common Stock	SSaleDisposed	−13,063	$58.31^F4	−$761,703.53	1,057,620	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.36 to $58.00, inclusive.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.75 to $58.88, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)